CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-30 | Blum Robert I President & CEO | Sale 10b5-1 | −11,500 | $59.49 | $684K | 399,412 |
| 2024-07-30 | Blum Robert I President & CEO | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −11,500 | 101,227 | ||
| 2024-07-29 | PARSHALL B LYNNE Director | Option exercise 10b5-1 | +5,000 | $21.61 | $108K | 25,600 |
| 2024-07-29 | PARSHALL B LYNNE Director | Sale 10b5-1 | −5,000 | $59.84 | $299K | 20,600 |
| 2024-07-29 | PARSHALL B LYNNE Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,000 | 15,000 | ||
| 2024-07-23 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $57.02 | $114K | 129,004 |
| 2024-07-23 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +5,300 | $7.96 | $42K | 134,304 |
| 2024-07-23 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −5,300 | $57.02 | $302K | 129,004 |
| 2024-07-23 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,300 | 53,000 | ||
| 2024-07-15 | PARSHALL B LYNNE Director | Option exercise 10b5-1 | +5,000 | $10.68 | $53K | 25,600 |
| 2024-07-15 | PARSHALL B LYNNE Director | Sale 10b5-1 | −5,000 | $55.82 | $279K | 20,600 |
| 2024-07-15 | PARSHALL B LYNNE Director | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,000 | 0 | ||
| 2024-07-10 | Blum Robert I President & CEO | Option exercise 10b5-1 | +5,767 | $6.67 | $38K | 410,912 |
| 2024-07-10 | Blum Robert I President & CEO | Sale 10b5-1 | −11,500 | $54.29 | $624K | 399,412 |
| 2024-07-10 | Blum Robert I President & CEO | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,767 | 112,727 | ||
| 2024-07-09 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +5,300 | $7.96 | $42K | 138,304 |
| 2024-07-09 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −5,300 | $55.91 | $296K | 133,004 |
| 2024-07-09 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −2,000 | $55.89 | $112K | 131,004 |
| 2024-07-09 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −5,300 | 58,300 | ||
| 2024-07-05 | Harrington Robert Arthur Director | Sale 10b5-1 | −253 | $54.61 | $14K | 15,516 |
Page 30 of 33 · 660 trades